FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2941036014> ?p ?o ?g. }

• W2941036014 endingPage "114" @default.
• W2941036014 startingPage "109" @default.
• W2941036014 abstract "Background Edaravone Dexborneol is a novel neuroprotective agent that comprised edaravone and (+)-borneol, a food additive with an anti-inflammatory effect in animal ischaemic stroke models. This study aims to assess the safety and efficacy of Edaravone Dexborneol compared with edaravone in treating patients with acute ischaemic stroke (AIS). Methods In this multicentre, randomised, double-blind, multiple-dose, active-controlled, phase II clinical trial, patients with AIS within 48 hours after stroke onset were randomly assigned (1:1:1:1) to low-dose (12.5 mg), medium-dose (37.5 mg) or high-dose (62.5 mg) Edaravone Dexborneol groups, and an active control group with edaravone (30 mg) by 30 min intravenous infusion every 12 hours, for 14 consecutive days. The primary efficacy outcome was the proportion of modified Rankin Scale (mRS)score ≤1 at 90 days and National Institutes of Health Stroke Scale (NIHSS) score change from baseline to 14 days after randomisation. The safety outcome included any adverse event during 90 days after treatment. Results Of 385 patients included in the efficacy analysis, 94 were randomised to low-dose group, 97 to medium-dose group, 98 to high-dose group and 96 to the control group. No significant difference was observed among the four groups on mRS score (mRS ≤1, p=0.4054) at 90 days or NIHSS score change at 14 days (p=0.6799). However, a numerically higher percentage of patients with mRSscore ≤1 at 90 days in the medium-dose (69.39%) and high-dose (65.63%) groups was observed than in the control group (60.64%). No significant difference in severe adverse events was found among the four groups (p=0.3815). Conclusions Compared with edaravone alone, Edaravone Dexborneol was safe and well tolerated at all doses, although no significant improvement in functional outcomes was observed at 90days. Trial registration number NCT01929096 ." @default.
• W2941036014 created "2019-05-03" @default.
• W2941036014 creator A5001749038 @default.
• W2941036014 creator A5002040792 @default.
• W2941036014 creator A5046732096 @default.
• W2941036014 creator A5056770759 @default.
• W2941036014 creator A5070578002 @default.
• W2941036014 creator A5075844545 @default.
• W2941036014 creator A5087669937 @default.
• W2941036014 creator A5087698913 @default.
• W2941036014 date "2019-04-22" @default.
• W2941036014 modified "2023-10-16" @default.
• W2941036014 title "Safety and efficacy of Edaravone Dexborneol versus edaravone for patients with acute ischaemic stroke: a phase II, multicentre, randomised, double-blind, multiple-dose, active-controlled clinical trial" @default.
• W2941036014 cites W1967296145 @default.
• W2941036014 cites W1981881424 @default.
• W2941036014 cites W1991663943 @default.
• W2941036014 cites W1994746821 @default.
• W2941036014 cites W2016245104 @default.
• W2941036014 cites W2022507627 @default.
• W2941036014 cites W2025112468 @default.
• W2941036014 cites W2030569641 @default.
• W2941036014 cites W2045803099 @default.
• W2941036014 cites W2047272367 @default.
• W2941036014 cites W2052438099 @default.
• W2941036014 cites W2067757696 @default.
• W2941036014 cites W2073200722 @default.
• W2941036014 cites W2074534400 @default.
• W2941036014 cites W2083548474 @default.
• W2941036014 cites W2088354749 @default.
• W2941036014 cites W2095856656 @default.
• W2941036014 cites W2098082628 @default.
• W2941036014 cites W2105651021 @default.
• W2941036014 cites W2188308812 @default.
• W2941036014 cites W2323001691 @default.
• W2941036014 cites W2351673993 @default.
• W2941036014 cites W2592988020 @default.
• W2941036014 cites W32784925 @default.
• W2941036014 cites W4245092639 @default.
• W2941036014 doi "https://doi.org/10.1136/svn-2018-000221" @default.
• W2941036014 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6812637" @default.
• W2941036014 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31709115" @default.
• W2941036014 hasPublicationYear "2019" @default.
• W2941036014 type Work @default.
• W2941036014 sameAs 2941036014 @default.
• W2941036014 citedByCount "34" @default.
• W2941036014 countsByYear W29410360142021 @default.
• W2941036014 countsByYear W29410360142022 @default.
• W2941036014 countsByYear W29410360142023 @default.
• W2941036014 crossrefType "journal-article" @default.
• W2941036014 hasAuthorship W2941036014A5001749038 @default.
• W2941036014 hasAuthorship W2941036014A5002040792 @default.
• W2941036014 hasAuthorship W2941036014A5046732096 @default.
• W2941036014 hasAuthorship W2941036014A5056770759 @default.
• W2941036014 hasAuthorship W2941036014A5070578002 @default.
• W2941036014 hasAuthorship W2941036014A5075844545 @default.
• W2941036014 hasAuthorship W2941036014A5087669937 @default.
• W2941036014 hasAuthorship W2941036014A5087698913 @default.
• W2941036014 hasBestOaLocation W29410360141 @default.
• W2941036014 hasConcept C126322002 @default.
• W2941036014 hasConcept C127413603 @default.
• W2941036014 hasConcept C168563851 @default.
• W2941036014 hasConcept C197934379 @default.
• W2941036014 hasConcept C2779554857 @default.
• W2941036014 hasConcept C2780645631 @default.
• W2941036014 hasConcept C2780931571 @default.
• W2941036014 hasConcept C3020199598 @default.
• W2941036014 hasConcept C42219234 @default.
• W2941036014 hasConcept C535046627 @default.
• W2941036014 hasConcept C541997718 @default.
• W2941036014 hasConcept C71924100 @default.
• W2941036014 hasConcept C78519656 @default.
• W2941036014 hasConceptScore W2941036014C126322002 @default.
• W2941036014 hasConceptScore W2941036014C127413603 @default.
• W2941036014 hasConceptScore W2941036014C168563851 @default.
• W2941036014 hasConceptScore W2941036014C197934379 @default.
• W2941036014 hasConceptScore W2941036014C2779554857 @default.
• W2941036014 hasConceptScore W2941036014C2780645631 @default.
• W2941036014 hasConceptScore W2941036014C2780931571 @default.
• W2941036014 hasConceptScore W2941036014C3020199598 @default.
• W2941036014 hasConceptScore W2941036014C42219234 @default.
• W2941036014 hasConceptScore W2941036014C535046627 @default.
• W2941036014 hasConceptScore W2941036014C541997718 @default.
• W2941036014 hasConceptScore W2941036014C71924100 @default.
• W2941036014 hasConceptScore W2941036014C78519656 @default.
• W2941036014 hasIssue "3" @default.
• W2941036014 hasLocation W29410360141 @default.
• W2941036014 hasLocation W29410360142 @default.
• W2941036014 hasLocation W29410360143 @default.
• W2941036014 hasOpenAccess W2941036014 @default.
• W2941036014 hasPrimaryLocation W29410360141 @default.
• W2941036014 hasRelatedWork W2046165793 @default.
• W2941036014 hasRelatedWork W2151055751 @default.
• W2941036014 hasRelatedWork W2188308812 @default.
• W2941036014 hasRelatedWork W2466087609 @default.
• W2941036014 hasRelatedWork W25275278 @default.
• W2941036014 hasRelatedWork W2549135832 @default.
• W2941036014 hasRelatedWork W2746532426 @default.
• W2941036014 hasRelatedWork W2787733414 @default.

• next